drugset / Trial / NCT05792163
A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease
RandomizedSequentialDouble-blindTreatment
Summary
SNP318 is developed to treat neurodegenerative diseases including Alzheimer's disease. In the current phase 1 study, the IP is tested in healthy volunteers, and the purpose is to investigate the safety, tolerability, and PK of single and multiple ascending oral doses of SNP318.
Timeline
- Start
- 2023-03-20
- Primary completion
- 2023-11-29
- Completion
- 2023-11-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SNP318 | Small molecule | 1 mg | Oral |
| Subject | SNP318 | Small molecule | 30 mg | Oral |